These findings demonstrate that the IGF2BP3-induced phenotypic effects observed in vitro can be recapitulated in clinical specimens and that it is possible to exploit this knowledge in the clinical settings for monitoring tumor progression. The gene discussed is IGF2BP3; the disease is neoplasm.